Effectiveness and response predictors of omalizumab in population with a high prevalence of comorbidities: the

Internal Medicine Journal 46, 1054-1062 DOI: 10.1111/imj.13166

Citation Report

#	Article	IF	CITATIONS
1	Herbal Medicine <i>Cordyceps sinensis</i> Improves Health-Related Quality of Life in Moderate-to-Severe Asthma. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-8.	1.2	20
2	Asthma or asthma OPD overlap syndrome? – Reply. Respirology, 2017, 22, 612-613.	2.3	1
3	Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Therapeutic Advances in Chronic Disease, 2017, 8, 31-45.	2.5	7
4	Severe asthma: Current management, targeted therapies and future directions—A roundtable report. Respirology, 2017, 22, 53-60.	2.3	50
5	Role of Obesity in Asthma: Mechanisms and Management Strategies. Current Allergy and Asthma Reports, 2017, 17, 53.	5.3	39
6	Management of severe asthma: targeting the airways, comorbidities and risk factors. Internal Medicine Journal, 2017, 47, 623-631.	0.8	30
7	Coâ€morbidities in severe asthma: <scp>C</scp> linical impact and management. Respirology, 2017, 22, 651-661.	2.3	172
8	Multidimensional assessment of severe asthma: A systematic review and metaâ€analysis. Respirology, 2017, 22, 1262-1275.	2.3	82
9	Omalizumab Treatment Response in a Population With Severe Allergic Asthma andÂOverlapping COPD. Chest, 2017, 151, 78-89.	0.8	90
10	Drugs that Act on the Respiratory Tract. Side Effects of Drugs Annual, 2017, , 161-171.	0.6	0
11	Nonadherence in the era of severe asthma biologics and thermoplasty. European Respiratory Journal, 2018, 51, 1701836.	6.7	85
12	Aryl hydrocarbon receptor activation by diesel exhaust particles mediates epitheliumâ€derived cytokines expression in severe allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2192-2204.	5.7	71
13	Factors reducing omalizumab response in severe asthma. European Journal of Internal Medicine, 2018, 52, 78-85.	2.2	40
14	Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. European Clinical Respiratory Journal, 2018, 5, 1440868.	1.5	40
15	Biologic agents for severe asthma patients: clinical perspectives and implications. Internal and Emergency Medicine, 2018, 13, 155-176.	2.0	13
16	Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Current Medical Research and Opinion, 2018, 34, 2075-2088.	1.9	72
17	Local allergic rhinitis: Implications for management. Clinical and Experimental Allergy, 2019, 49, 6-16.	2.9	86
18	Nonallergic Triggers and Comorbidities in Asthma Exacerbations and Disease Severity. Clinics in Chest Medicine, 2019, 40, 71-85.	2.1	6

#	Article	IF	CITATIONS
19	Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children. Asia Pacific Allergy, 2019, 9, e7.	1.3	5
20	Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology, 2019, 15, 553-569.	3.0	56
21	Particularités de l'asthme tardif non allergique des patients obèses. Revue Des Maladies Respiratoires Actualites, 2019, 11, 69-74.	0.0	0
22	Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 276-293.	5.6	182
23	Rational oral corticosteroid use in adult severe asthma: A narrative review. Respirology, 2020, 25, 161-172.	2.3	58
25	Contemporary management techniques of asthma in obese patients. Expert Review of Respiratory Medicine, 2020, 14, 249-257.	2.5	2
26	Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 739-741.e6.	3.8	11
27	International Severe Asthma Registry. Chest, 2020, 157, 805-814.	0.8	38
28	The impact of clinical and psychological factors on asthma control: the experience of a single asthma center in Poland. Journal of Asthma, 2020, , 1-11.	1.7	1
29	An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma. Expert Review of Respiratory Medicine, 2020, 14, 1197-1205.	2.5	15
30	How to apply the personalized medicine in obesity-associated asthma?. Expert Review of Respiratory Medicine, 2020, 14, 905-915.	2.5	4
31	Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3428-3433.e1.	3.8	21
32	The evolving algorithm of biological selection in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1555-1563.	5.7	30
33	Mepolizumab effectiveness and identification of super-responders in severe asthma. European Respiratory Journal, 2020, 55, 1902420.	6.7	124
34	Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. Journal of Asthma, 2021, 58, 448-458.	1.7	30
35	Effectiveness and Response Predictors of Omalizumab in Treating Patients with Seasonal Allergic Rhinitis: A Real-World Study. Journal of Asthma and Allergy, 2021, Volume 14, 59-66.	3.4	6
36	Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2702-2714.	3.8	62
37	Research Progress of Omalizumab in the Treatment of Allergic Asthma. Advances in Clinical Medicine, 2021, 11, 682-689.	0.0	0

	CITATION	tion Report	
#	Article	IF	Citations
38	Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. International Journal of Molecular Sciences, 2021, 22, 7132.	4.1	6
39	Asthme et obésité de l'adulte. Medecine Des Maladies Metaboliques, 2021, 16, 89-89.	0.1	0
40	Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. Respirology, 2021, 26, 1112-1130.	2.3	35
41	FASE-CPHG study: a panoramic snapshot of difficult-to-treat, severe asthma in French nonacademic hospitals. ERJ Open Research, 2019, 5, 00069-2019.	2.6	11
42	The contribution of comorbidities, psychosocial factors and adherence to the presentation of severe asthma. , 2019, , 30-47.		1
43	Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control. Jornal Brasileiro De Pneumologia, 2017, 43, 487-489.	0.7	6
44	A Possible Explanation for Non-responders, Responders and Super-responders to Biologics in Severe Asthma. Exploratory Research and Hypothesis in Medicine, 2019, X, 1-4.	0.4	0
45	Severe asthma management in adults. , 2019, , 315-326.		0
46	A Possible Explanation for Non-responders, Responders and Super-responders to Biologics in Severe Asthma. Exploratory Research and Hypothesis in Medicine, 2019, X, 1-4.	0.4	1
47	Metabolic dysfunction and severe asthma. , 2019, , 195-210.		0
48	Practical Considerations in Management of Obesity-Associated Asthma. Respiratory Medicine, 2020, , 229-241.	0.1	0
49	A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. Respiratory Medicine, 2022, 191, 106670.	2.9	23
50	Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine, 2022, 12, 165.	2.5	5
51	Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma. Annals of Allergy, Asthma and Immunology, 2022, 128, 553-560.	1.0	9
52	The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma. Korean Journal of Internal Medicine, 2022, 37, 249-260.	1.7	6
53	2021 Brazilian Thoracic Association recommendations for the management of severe asthma. Jornal Brasileiro De Pneumologia, 2021, 47, e20210273.	0.7	9
54	Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges?. ERJ Open Research, 2022, 8, 00670-2021.	2.6	2
55	Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis. Expert Review of Respiratory Medicine, 2022, 16, 1023-1033.	2.5	6

CITATION REPORT

#	Article	IF	CITATIONS
56	Extracellular Traps: A Novel Therapeutic Target for Severe Asthma. Journal of Asthma and Allergy, 0, Volume 15, 803-810.	3.4	5
57	Critical evaluation of asthma biomarkers in clinical practice. Frontiers in Medicine, 0, 9, .	2.6	19
58	Roles of real-world evidence in severe asthma treatment: challenges and opportunities. ERJ Open Research, 2023, 9, 00248-2022.	2.6	2
59	Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma. Frontiers in Medicine, 0, 10, .	2.6	1
60	Effect of obesity on airway and systemic inflammation in adults with asthma: a systematic review and meta-analysis. Thorax, 2023, 78, 957-965.	5.6	6
61	Gaps and Future Directions in Clinical Research on Obesity-Related Asthma. Pulmonary Therapy, 2023, 9, 309-327.	2.2	2
62	Characterization of Obesity in Severe Asthma in the German Asthma Net. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 3417-3424.e3.	3.8	5
63	Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy: European Journal of Allergy and Clinical Immunology, 2024, 79, 384-392.	5.7	3
64	Real-life studies and registries of severe asthma: The advent of digital technology. Respiratory Medicine, 2023, 220, 107429.	2.9	0
65	Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma. Annals of Allergy, Asthma and Immunology, 2023, , .	1.0	0
66	Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity. Frontiers in Pharmacology, 0, 14, .	3.5	0
67	The phenotypic heterogeneity of obese and nonobese patients with severe asthma and comparison of omalizumab–mepolizumab treatment efficiency in these patients. Medicine (United States), 2023, 102, e35247.	1.0	0
68	Associations of asthma control with hypertension, cardiovascular disease, and mortality in obese individuals. Internal and Emergency Medicine, 0, , .	2.0	0